In interpreting the findings of this review, it is also essential to critically evaluate whether trial design factors, patient selection criteria or choice of outcome measures may have contributed to the observed lack of significant benefit from IL-1 inhibitors in severe alcoholic hepatitis. Here, IL1B is linked to alcoholic hepatitis.